Company Description
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer.
Its lead product candidate includes ziftomenib, a selective investigational inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a selective investigational FTI for the treatment of solid tumors.
It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies; and a clinical collaboration with Mirati Therapeutics, Inc. to evaluate the combination of KO-2806 and adagrasib, a KRASG12C inhibitor in patients with NSCLC.
The company is headquartered in San Diego, California.
Country | United States |
Founded | 2014 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 192 |
CEO | Troy Wilson |
Contact Details
Address: 12730 High Bluff Drive, Suite 400 San Diego, California 92130 United States | |
Phone | 858 500 8800 |
Website | kuraoncology.com |
Stock Details
Ticker Symbol | KURA |
Exchange | NASDAQ |
Stock Type | Common Stock |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001422143 |
CUSIP Number | 50127T109 |
ISIN Number | US50127T1097 |
Employer ID | 61-1547851 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Troy Edward Wilson J.D., Ph.D. | Chairman, Chief Executive Officer and President |
Kathleen Ford | Chief Operating Officer |
Teresa Brophy Bair Esq., J.D. | Chief Legal Officer and Corporate Secretary |
Thomas Doyle | Senior Vice President of Finance and Accounting |
Dr. Francis J. Burrows Ph.D. | Chief Scientific Officer |
Dr. Roger Bakale Ph.D. | Senior Vice President of Manufacturing and Supply Chain |
Maureen Clancy M.B.A. | Vice President and Global Head of Program Leadership and Project Management |
Dr. Mollie Leoni M.D. | Chief Medical Officer |
Brian T. Powl M.B.A., M.S. | Chief Commercial Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
May 1, 2025 | 10-Q | Quarterly Report |
May 1, 2025 | 8-K | Current Report |
Apr 17, 2025 | ARS | Filing |
Apr 17, 2025 | SCHEDULE 13G/A | Filing |
Apr 11, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
Apr 11, 2025 | DEF 14A | Other definitive proxy statements |
Mar 21, 2025 | 144 | Filing |
Feb 28, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
Feb 28, 2025 | 10-K | Annual Report |
Feb 26, 2025 | 8-K | Current Report |